Last Price$1.3(9.4%)
Market Cap$8,155.2K
LTM Return on Equity (ROE)
(461.0%)
5Y avg
(158.3%)
Medical - Instruments & Supplies industry
median
(7.1%)
Stock quality & Intrinsic value
4/10
3.0% undervalued
Predictive Oncology Inc. Return on Equity (ROE)
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 569.6% | 218.2% | 59.7% | 183.4% | 247.1% | 288.5% | 156.5% | 682.6% | (259.2%) | (428.5%) | (734.8%) | (343.7%) | (373.1%) | (91.6%) | (83.0%) | (93.1%) |
Overvalued or undervalued?
Check the intrinsic value for POAI
and see if it's the right time to invest.
Predictive Oncology Inc. (POAI) Return on Equity (ROE) comparison analysis
General
LTM Return on Equity (ROE)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Predictive Oncology Inc.POAI
(461.0%)
18.2%
(64.9%)
(785.6%)
Median Peer Set
10.2%
3.4%
23.0%
10.4%
ResMed Inc.RMD
23.9%
10.9%
13.4%
21.8%
West Pharmaceutical Services, Inc.WST
18.1%
(1.9%)
(15.5%)
17.0%
Hologic, Inc.HOLX
15.0%
(0.0%)
81.1%
19.6%
AptarGroup, Inc.ATR
14.9%
2.7%
30.2%
10.5%
Intuitive Surgical, Inc.ISRG
14.5%
17.2%
27.7%
27.8%
Becton, Dickinson and CompanyBDX
5.9%
4.2%
18.3%
8.4%
The Cooper Companies, Inc.COO
4.9%
8.4%
32.2%
10.1%
Alcon Inc.ALC
4.4%
8.5%
182.9%
10.3%
Baxter International Inc.BAX
(8.2%)
(69.5%)
(100.0%)
(6.9%)
Masimo CorporationMASI
(24.2%)
0.6%
(42.5%)
4.0%
POAI key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 (98.2%) | 0.1 33,454.5% | 0.2 95.3% | 0.5 148.0% | 1.0 103.3% | 0.7 (31.2%) | 0.5 (30.2%) | 0.7 43.4% | 1.4 115.6% | 1.4 (0.0%) | 1.3 (11.3%) | 1.4 13.4% | 1.5 6.0% | 1.8 18.2% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.1 | 0.4 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 |
% margin | 0.0 0.0% | 0.0 55.5% | 0.0 51.4% | 0.0 42.0% | 0.1 31.9% | 0.3 59.5% | 0.6 59.5% | 0.4 53.5% | 0.3 60.2% | 0.5 77.4% | 1.0 70.5% | 0.9 62.3% | 0.8 64.3% | 0.9 65.7% | 1.0 66.4% | 1.1 64.3% |
| Operating Expenses | 1.7 | 2.5 | 1.2 | 4.1 | 7.2 | 9.2 | 7.0 | 4.8 | 6.8 | 8.3 | 8.9 | 14.7 | 13.3 | 14.4 | 16.3 | 15.1 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | 0.3 | 0.4 | 0.3 | 1.9 | 3.0 | 2.4 | 0.3 | 0.3 | 0.2 |
| Selling, General & Administrative Expenses (SG&A) | 1.4 | 2.0 | 2.1 | 4.1 | 7.2 | 9.2 | 7.0 | 4.8 | 5.6 | 8.3 | 7.0 | 11.7 | 10.9 | 11.7 | 12.5 | 10.9 |
% margin | (1.7) 0.0% | (2.4) (15,528.1%) | (1.2) (418,616.7%) | (4.1) (4,248.3%) | (7.2) (3,792.8%) | (8.9) (1,907.1%) | (6.5) (679.7%) | (4.4) (672.4%) | (6.5) (1,429.6%) | (7.7) (1,183.0%) | (7.9) (556.9%) | (13.8) (975.8%) | (0.7) (53.2%) | (13.5) (948.2%) | (15.3) (1,014.2%) | (13.9) (782.1%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.6 | 0.4 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.7 | 0.0 |
| Pre-tax Income | 0.0 | (1.8) | (1.4) | (4.5) | (7.4) | (9.4) | (6.8) | (4.8) | (6.5) | (7.7) | (10.1) | (19.4) | (25.9) | (20.3) | (25.7) | (14.0) |
% effective tax rate | 0.1 0.0% | 0.4 (25.4%) | 0.0 0.0% | 0.2 (5.1%) | 0.3 (3.5%) | 0.6 (6.8%) | 0.4 (5.5%) | 0.0 0.0% | 0.0 0.0% | 0.1 (0.7%) | (2.2) 22.1% | 8.2 (42.1%) | 11.8 (45.7%) | (0.7) 3.3% | 10.5 (40.7%) | 0.0 0.0% |
% margin | (1.8) 0.0% | (2.9) (18,378.5%) | (1.4) (469,690.6%) | (4.5) (4,643.0%) | (7.4) (3,931.8%) | (9.4) (2,009.4%) | (6.8) (718.1%) | (4.8) (732.1%) | (6.5) (1,429.6%) | (7.7) (1,183.0%) | (10.1) (714.5%) | (27.6) (1,952.2%) | (37.7) (3,010.7%) | (19.7) (1,383.6%) | (36.2) (2,405.1%) | (14.0) (785.6%) |
| EPS | (65,282.52) | (96,407.67) | (36,559.70) | (52,786.81) | (26,794.78) | (16,051.71) | (11,057.55) | (4,601.85) | (462.31) | (243.50) | (157.40) | (192.02) | (63.10) | (7.16) | (9.92) | (3.48) |
| Diluted EPS | (65,282.52) | (96,407.67) | (36,559.70) | (52,786.81) | (26,794.78) | (16,051.71) | (11,057.55) | (4,601.85) | (462.31) | (243.50) | (157.40) | (192.02) | (63.10) | (7.16) | (9.92) | (3.48) |
% margin | (1.7) 0.0% | (2.8) (17,857.6%) | (1.2) (417,773.3%) | (4.3) (4,401.3%) | (7.2) (3,793.9%) | (8.8) (1,871.6%) | (6.4) (671.8%) | (4.3) (660.4%) | (6.4) (1,411.5%) | (6.0) (913.5%) | (7.7) (546.4%) | (12.4) (879.4%) | (11.5) (915.0%) | (12.1) (853.9%) | (14.0) (926.9%) | (13.2) (740.5%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Predictive Oncology Inc.'s Return on Equity (ROE)?
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is (461.0%), based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Return on Equity (ROE) for Predictive Oncology Inc. have been (143.6%) over the past three years, and (166.2%) over the past five years.
2) Is Predictive Oncology Inc.'s Return on Equity (ROE) Good?
As of today, Predictive Oncology Inc.'s Return on Equity (ROE) is (461.0%), which is lower than industry median of (7.1%). It indicates that Predictive Oncology Inc.'s Return on Equity (ROE) is Bad.